#China #Beijing #Jacobio Pharma #R&D #glecirasib

Jacobio Pharma Reports 2024 Annual Results

Jacobio Pharma, known for its innovative approach to oncology treatments, has recently published its annual results for 2024, marking a significant step in the company’s trajectory. The report reveals that the company achieved revenues of RMB160 million, coupled with an investment of RMB330 million in research and development (R&D). These figures highlight Jacobio's commitment to pushing the boundaries of cancer treatment research.

Financial Overview

The company’s operating and financing activities have proven fruitful, generating cash inflows amounting to RMB320 million. By the close of 2024, Jacobio reported a robust financial position with cash and bank balances including credit facilities reaching RMB1.45 billion. This strong foundation positions the company favorably for future growth and innovation.

Dr. Yinxiang Wang, the Chairman and CEO of Jacobio Pharma, described 2024 as a transformative year for the organization. Notably, the company has submitted a New Drug Application (NDA) for its KRAS G12C inhibitor, glecirasib. Additionally, it has entered into a licensing agreement to allow the commercialization rights of glecirasib and its SHP2 inhibitor, sitneprotafib, to be handled by another partner. This shift underscores Jacobio's evolution from a focus on early-stage R&D to a more mature, value-driven business model.

Looking ahead, Dr. Wang expressed optimism regarding the anticipated approval of glecirasib in 2025. The introduction of this groundbreaking treatment is expected to bolster cash flow, enabling further investment in Jacobio’s expansive pipeline of oncology treatments.

Advancements in Clinical Trials

The progress made in clinical trials during 2024 has been noteworthy. Jacobio is advancing its clinical-stage products, focusing on:

• - Glecirasib (JAB-21822): A targeted therapy for KRAS G12C mutations, primarily aimed at combating non-small cell lung cancer (NSCLC). The NDA for glecirasib as a standalone treatment for second-line NSCLC was submitted in May 2024 and has been granted priority review. The approval is expected in the first half of 2025.
• - Sitneprotafib (JAB-3312): This SHP2 inhibitor, alongside glecirasib, is currently undergoing pivotal trials in NSCLC, with the first patient being enrolled in August 2024.

Furthermore, Jacobio has initiated a multi-tumor basket registration phase II trial for glecirasib, targeting pancreatic cancer, biliary tract cancer, and several others. Notably, glecirasib has received orphan drug designations from both the FDA and EMA for its potential in pancreatic cancer, signifying its importance in treating rare but aggressive malignancies.

Pipeline Breakthroughs

Jacobio is not only focused on clinical growth but is also nurturing a rich pre-clinical pipeline. Some key highlights include:

• - JAB-23E73: A pan-KRAS inhibitor whose IND application has been approved in both China and the U.S. The first patient was recruited in late 2024, and the dose escalation phase is set to conclude in 2025.
• - JAB-30355: A p53 Y220C activator with IND applications approved in 2024, paving the way for its first-in-human trial.
• - JAB-2485: An Aurora A inhibitor undergoing a Phase I/IIa trial that anticipates the phase transition to be complete in early 2025.

For its future endeavors, Jacobio plans on submitting IND applications for two innovative therapies in the upcoming years: HER2-STING iADC and KRAS G12D ADC, emphasizing its commitment to pioneering drug development.

Intellectual Property and Future Calls

As of the end of 2024, Jacobio has successfully filed over 360 patent applications globally, securing 126 patents. This extensive intellectual property portfolio underpins the company's innovative research and assures its competitive edge in the biotechnology sector.

Jacobio Pharma is slated to hold a conference call on March 20, 2024, inviting stakeholders to discuss further progress and prospects. This commitment to transparency exemplifies the company’s goal of fostering a community around its innovations.

Conclusion

In summary, Jacobio Pharma’s 2024 results not only reflect a strong financial standing but also paint a promising picture of its development in the oncology landscape. With significant R&D investments and a suite of novel therapies in the pipeline, Jacobio continues to position itself as a leader in the fight against cancer. Stakeholders and investors alike have much to anticipate as Jacobio navigates the coming years in an ever-evolving medical environment.